ES2422291T3 - Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas - Google Patents

Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas

Info

Publication number
ES2422291T3
ES2422291T3 ES08845549T ES08845549T ES2422291T3 ES 2422291 T3 ES2422291 T3 ES 2422291T3 ES 08845549 T ES08845549 T ES 08845549T ES 08845549 T ES08845549 T ES 08845549T ES 2422291 T3 ES2422291 T3 ES 2422291T3
Authority
ES
Spain
Prior art keywords
semisite
recognition
seq
recognition sequences
laglidadg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08845549T
Other languages
English (en)
Spanish (es)
Inventor
James Jefferson Smith
Derek Jantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biosciences Inc
Original Assignee
Precision Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biosciences Inc filed Critical Precision Biosciences Inc
Application granted granted Critical
Publication of ES2422291T3 publication Critical patent/ES2422291T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ES08845549T 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas Active ES2422291T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US124707P 2007-10-31 2007-10-31
PCT/US2008/082072 WO2009059195A2 (en) 2007-10-31 2008-10-31 Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

Publications (1)

Publication Number Publication Date
ES2422291T3 true ES2422291T3 (es) 2013-09-10

Family

ID=40591777

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08845549T Active ES2422291T3 (es) 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
ES16163925T Active ES2732735T3 (es) 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
ES13165733.0T Active ES2575412T3 (es) 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16163925T Active ES2732735T3 (es) 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
ES13165733.0T Active ES2575412T3 (es) 2007-10-31 2008-10-31 Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas

Country Status (8)

Country Link
US (10) US8445251B2 (enExample)
EP (4) EP3098309B1 (enExample)
JP (7) JP5761996B2 (enExample)
AU (1) AU2008318430A1 (enExample)
CA (1) CA2704383A1 (enExample)
DK (3) DK2215223T3 (enExample)
ES (3) ES2422291T3 (enExample)
WO (1) WO2009059195A2 (enExample)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US8206965B2 (en) † 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
AU2010325563B2 (en) 2009-11-27 2017-02-02 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
CN102725412B (zh) 2009-11-27 2017-09-22 巴斯夫植物科学有限公司 优化的内切核酸酶及其用途
US20130198897A1 (en) 2010-03-22 2013-08-01 Philip Morris Products S.A. Modifying enzyme activity in plants
WO2012138901A1 (en) * 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
AU2015229299A1 (en) 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
US20180344817A1 (en) 2015-05-01 2018-12-06 Precision Biosciences, Inc. Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
US10662440B2 (en) 2015-06-19 2020-05-26 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017024407A1 (en) 2015-08-11 2017-02-16 The Royal Institution For The Advancement Of Learning/Mcgill University Peptidic tgf-beta antagonists
CA2997909A1 (en) 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
US20190017075A1 (en) 2015-12-23 2019-01-17 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
US11274288B2 (en) 2016-02-16 2022-03-15 Emendobio Inc. Compositions and methods for promoting homology directed repair mediated gene editing
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3448380B1 (en) 2016-04-27 2021-12-01 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
EP3452583B1 (en) 2016-05-03 2021-10-27 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
AR108853A1 (es) 2016-06-22 2018-10-03 Univ North Carolina State Método para aumentar la eficacia en el uso de nitrógeno y/o la eficiencia en la utilización del nitrógeno en las plantas
CA3031785A1 (en) * 2016-07-25 2018-02-01 Bluebird Bio, Inc. Bcl11a homing endonuclease variants, compositions, and methods of use
US20190262398A1 (en) 2016-08-23 2019-08-29 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
SG11201901757YA (en) 2016-09-08 2019-03-28 Bluebird Bio Inc Pd-1 homing endonuclease variants, compositions, and methods of use
DK3757120T3 (da) 2016-10-04 2022-07-25 Prec Biosciences Inc Co-stimulerende domæner til anvendelse i genetisk modificerede celler
KR20230010826A (ko) * 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
US11530395B2 (en) 2016-10-17 2022-12-20 2Seventy Bio, Inc. TGFBetaR2 endonuclease variants, compositions, and methods of use
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US10457683B2 (en) 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
EP4269596A3 (en) * 2017-04-21 2024-02-14 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
US20200190541A1 (en) 2017-04-28 2020-06-18 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
JP7170666B2 (ja) 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ，インク． 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
IL270776B2 (en) 2017-05-25 2024-11-01 Bluebird Bio Inc Cblb endonuclease variants, compositions, and methods of use
US12139718B2 (en) 2017-06-23 2024-11-12 University Of Kentucky Research Foundation Methods of decreasing total alkaloid content in tobacco
EP4775669A2 (en) 2017-06-30 2026-07-15 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
JP2020529206A (ja) 2017-07-31 2020-10-08 アール・ジエイ・レイノルズ・タバコ・カンパニー 植物におけるウイルスベースの遺伝子編集のための方法及び組成物
EP3692057B9 (en) 2017-10-03 2023-10-04 Precision BioSciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
US11779654B2 (en) 2017-10-04 2023-10-10 2Seventy Bio, Inc. PCSK9 endonuclease variants, compositions, and methods of use
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3704238B1 (en) 2017-11-01 2024-01-03 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
IL275077B2 (en) 2017-12-06 2025-02-01 Magenta Therapeutics Inc Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
US20210002621A1 (en) * 2017-12-20 2021-01-07 Bluebird Bio, Inc. Ctla4 homing endonuclease variants, compositions, and methods of use
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
UA128937C2 (uk) 2018-01-09 2024-12-04 Сайбас Юес Ллс Рослина brassica napus, що має знижену сприйнятливість до розстріскування плодів до збирання урожаю, та спосіб її одержання
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス，インコーポレーテッド 寛容原性リポソーム及びその使用方法
EA202092382A1 (ru) 2018-04-04 2021-02-02 САЙБАС ЮЭс ЛЛС Гены fad2 и мутации
IT201800004253A1 (it) 2018-04-05 2019-10-05 Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
KR102617818B1 (ko) 2018-04-12 2023-12-27 프리시젼 바이오사이언시스 인코포레이티드 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019210213A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use
CN112368021B (zh) 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
GB201812603D0 (en) 2018-08-02 2018-09-19 British American Tobacco Investments Ltd Method
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
GB201818715D0 (en) 2018-11-16 2019-01-02 British American Tobacco Investments Ltd Method
JP2022513750A (ja) 2018-12-10 2022-02-09 ２セブンティ バイオ インコーポレイテッド ホーミングエンドヌクレアーゼバリアント
CA3122094A1 (en) 2018-12-10 2020-06-18 Bluebird Bio, Inc. Pdcd-1 homing endonuclease variants
EP3898661A1 (en) 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
GB201900940D0 (en) 2019-01-23 2019-03-13 British American Tobacco Investments Ltd Method
EP4332115A3 (en) 2019-04-03 2024-05-29 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
EP3947646A1 (en) 2019-04-05 2022-02-09 Precision BioSciences, Inc. Methods of preparing populations of genetically-modified immune cells
CN114026228A (zh) 2019-05-07 2022-02-08 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
GB201906768D0 (en) 2019-05-14 2019-06-26 British American Tobacco Investments Ltd Method
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
GB201909562D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
GB201909563D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
WO2021035054A1 (en) 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
US20220411479A1 (en) 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3835309A1 (en) 2019-12-13 2021-06-16 KWS SAAT SE & Co. KGaA Method for increasing cold or frost tolerance in a plant
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
JP2023521055A (ja) 2020-04-09 2023-05-23 アール・ジエイ・レイノルズ・タバコ・カンパニー ニコチアナ・タバカムにおけるニコチンレベルの調整方法
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
IL298138A (en) 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
EP4150068A1 (en) 2020-05-12 2023-03-22 Precision BioSciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
EP4192875A1 (en) 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
US20240011003A1 (en) 2020-08-21 2024-01-11 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
MX2023005113A (es) 2020-10-29 2023-08-04 Univ Pennsylvania Cápsides de aav y composiciones que las contienen.
KR20250099412A (ko) 2020-11-12 2025-07-01 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
CA3172161A1 (en) 2021-01-08 2022-07-14 James Jefferson Smith Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2022226316A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Compositions and methods for generating male sterile plants
IL307834A (en) 2021-04-22 2023-12-01 Prec Biosciences Inc Transgenic meganonucleases targeting human mitochondrial genomes
US20240200046A1 (en) * 2021-04-22 2024-06-20 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
MX2024004812A (es) 2021-10-19 2024-07-15 Prec Biosciences Inc Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat).
AU2022368911A1 (en) 2021-10-19 2024-05-30 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
KR20240132132A (ko) 2022-02-03 2024-09-02 니코벤처스 트레이딩 리미티드 담배 식물들에서 알칼로이드 함량을 조절하는 방법
WO2023148478A1 (en) 2022-02-03 2023-08-10 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
WO2023148475A1 (en) 2022-02-04 2023-08-10 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
GB202205148D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205149D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205561D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202205562D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202206109D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
GB202206107D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
AU2023392154A1 (en) 2022-12-14 2025-06-26 King's College London Compositions and methods for treating neurological diseases
IL321936A (en) 2023-01-05 2025-09-01 Prec Biosciences Inc Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene
GB202300905D0 (en) 2023-01-20 2023-03-08 Nicoventures Trading Ltd Method
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
KR20250141243A (ko) 2023-02-06 2025-09-26 블루록 테라퓨틱스 엘피 데그론 융합 단백질 및 그의 생산 및 사용 방법
GB202303077D0 (en) 2023-03-02 2023-04-19 Univ Oslo Brassica plants with improved seed retention
AU2024229544A1 (en) 2023-03-02 2025-10-16 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
CN121311497A (zh) 2023-04-14 2026-01-09 精密生物科学公司 肌肉特异性表达盒
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025083169A1 (en) 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025126153A2 (en) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions and methods for treating sod1-mediated neurological diseases
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026028165A1 (en) 2024-08-01 2026-02-05 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
WO2026154123A1 (en) 2025-01-17 2026-07-23 Aviadobio Limited Compositions and methods for treating neurological diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2002317771A1 (en) * 2001-06-05 2002-12-16 Cellectis Methods for modifying the cpg content of polynucleotides
EP1483298A4 (en) * 2002-02-11 2007-03-14 Zymogenetics Inc MATERIALS AND METHODS FOR PREPARING DIMERED GROWTH FACTORS
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
JP4095622B2 (ja) * 2004-03-31 2008-06-04 キヤノン株式会社 金結合性複合タンパク質
EP1591521A1 (en) * 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
EP1764414A1 (en) * 2005-09-17 2007-03-21 Icon Genetics AG Plant viral particles comprising a plurality of fusion proteins consisting of a plant viral coat protein, a peptide linker and a recombinant protein and use of such plant viral particles for protein purification
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
AU2006320246A1 (en) * 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
GB0603099D0 (en) * 2006-02-16 2006-03-29 Lontra Environmental Technolog Rotary piston and cylinder devices
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
WO2008059317A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
SG176487A1 (en) 2006-11-14 2011-12-29 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
AU2007347328B2 (en) 2007-02-19 2013-03-07 Cellectis LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
WO2008102199A1 (en) * 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
WO2008149176A1 (en) * 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
CA2691440A1 (en) 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2009074842A1 (en) 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof

Also Published As

Publication number Publication date
US20160002671A1 (en) 2016-01-07
US10041053B2 (en) 2018-08-07
DK3098309T3 (da) 2019-07-15
EP3098309B1 (en) 2019-04-10
EP2215223A2 (en) 2010-08-11
JP2021052770A (ja) 2021-04-08
WO2009059195A3 (en) 2009-09-03
DK2215223T3 (da) 2013-07-22
EP3578646A2 (en) 2019-12-11
JP2023029894A (ja) 2023-03-07
JP2015221035A (ja) 2015-12-10
JP2011501971A (ja) 2011-01-20
AU2008318430A1 (en) 2009-05-07
US20150337335A1 (en) 2015-11-26
US20100311817A1 (en) 2010-12-09
US9340777B2 (en) 2016-05-17
EP2215223A4 (en) 2011-01-05
US20160002615A1 (en) 2016-01-07
EP2660317A1 (en) 2013-11-06
DK2660317T3 (en) 2016-08-01
EP2215223B1 (en) 2013-05-01
US12351839B2 (en) 2025-07-08
US9434931B2 (en) 2016-09-06
EP3098309A1 (en) 2016-11-30
ES2575412T3 (es) 2016-06-28
US20210054354A1 (en) 2021-02-25
US20180340160A1 (en) 2018-11-29
CA2704383A1 (en) 2009-05-07
WO2009059195A2 (en) 2009-05-07
US20130267009A1 (en) 2013-10-10
JP2017051190A (ja) 2017-03-16
JP5761996B2 (ja) 2015-08-12
US20250154485A1 (en) 2025-05-15
EP2660317B1 (en) 2016-04-06
EP3578646A3 (en) 2020-03-18
JP2025028832A (ja) 2025-03-05
US8445251B2 (en) 2013-05-21
US20160222417A1 (en) 2016-08-04
JP6050861B2 (ja) 2016-12-21
JP2019062898A (ja) 2019-04-25
US20230416711A1 (en) 2023-12-28
EP3578646B1 (en) 2026-07-15
ES2732735T3 (es) 2019-11-25

Similar Documents

Publication Publication Date Title
MX2024015050A (es) L-asparaginasa modificada
PE20190802A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
MX353906B (es) Metodo para la produccion de acidos grasos poli-insaturados en organismos transgenicos.
AR065350A1 (es) Moleculas de acido nucleicos que codifican una alternanosucrasa truncada
MX2020005324A (es) Microorganismo modificado geneticamente para producir acido 3-hidroxidadipico, acido alfa-hidromuconico y/o acido adipico, y metodo de produccion para tales productos quimicos.
EA201991440A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
AR083848A1 (es) Polipeptidos con actividad de fosfolipasa c y polinucleotidos que los codifican
EA201891127A1 (ru) Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ES2543203T3 (es) Grupo de genes NRPS-PKS, su manipulación y su utilidad
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
AR076157A1 (es) Plantas con rendimiento aumentado (nue)
AR069362A1 (es) Variantes de enzimas asparraginasas y sus usos
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
WO2016130628A8 (en) Griffithsin mutants
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
JP2020529221A5 (enExample)
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
CN106467910A (zh) L-dna/l-rna聚合酶及其应用
AR075810A1 (es) Lipasa optimizadas por par de codones (cpo) y derivados de la misma
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.